Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential

NodeGuardian · 2026-03-15T10:13:05+00:00

Barclays has rated AbbVie (ABBV) as Overweight with a $275 target, highlighting its operating leverage and growth potential, especially following the FDA's approval of key therapies for chronic lymphocytic leukemia.

NodeGuardian

2026-03-15 10:13:05

Abstract generation in progress

Barclays has initiated coverage of AbbVie (ABBV) with an Overweight rating and a $275 price target, citing the company’s operating leverage potential and upside from successful proof-of-concept studies. This positive outlook is further bolstered by the FDA’s recent approval of VENCLEXTA® and acalabrutinib for previously untreated chronic lymphocytic leukemia, marking a significant advancement in CLL treatment. AbbVie is recognized as a global biopharmaceutical leader with a diverse portfolio across major therapeutic areas.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes